(NASDAQ: FLGT) Fulgent Genetics's forecast annual revenue growth rate of 12.64% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 8.53%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 57.66%.
Fulgent Genetics's revenue in 2026 is $315,549,000.On average, 5 Wall Street analysts forecast FLGT's revenue for 2026 to be $11,235,417,996, with the lowest FLGT revenue forecast at $10,745,456,583, and the highest FLGT revenue forecast at $11,593,383,496. On average, 5 Wall Street analysts forecast FLGT's revenue for 2027 to be $12,344,554,621, with the lowest FLGT revenue forecast at $11,829,863,294, and the highest FLGT revenue forecast at $12,752,907,320.
In 2028, FLGT is forecast to generate $13,561,266,370 in revenue, with the lowest revenue forecast at $13,029,573,228 and the highest revenue forecast at $13,960,345,351.